Arisco A M, Brantly E K, Kraus S R
University of Texas Health Science, Center at San Antonio, Department of Urology, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
Drug Des Devel Ther. 2009 Sep 21;3:151-61. doi: 10.2147/dddt.s3370.
Overactive bladder (OAB) is a common condition which negatively impacts the quality of life of afflicted patients. This can result in alterations in social interactions at home, in the workplace and in the community, often leading to depression and poor self esteem as well as loss of productivity. Traditional mainstays of treatment include both behavioral therapy and pharmacotherapy. Oxybutynin immediate release (IR) represents the first such medication approved by the FDA specifically for treatment of OAB in 1975. Nevertheless, bothersome side effects in addition to thrice daily dosing often led to treatment cessation which raised the question that patients may actually prefer to live with their OAB symptoms rather than incur side effects or complex dosing schemes. Pharmacological advances ultimately led to development of a long-acting formulation of oxybutynin in the form of oxybutynin extended release (ER) with the hope that this drug would maintain efficacy while decreasing bothersome side effects and improve compliance with the convenience of once daily dosing regimen. This paper will review the major clinical studies involving oxybutynin ER as well as its role in different patient populations and potential concerns with its use.
膀胱过度活动症（OAB）是一种常见病症，会对患病患者的生活质量产生负面影响。这可能导致患者在家庭、工作场所和社区中的社交互动发生改变，常常引发抑郁、自卑，以及生产力下降。传统的主要治疗方法包括行为疗法和药物疗法。奥昔布宁速释片（IR）是1975年美国食品药品监督管理局（FDA）专门批准用于治疗OAB的第一种此类药物。然而，除了每日三次给药外，令人烦恼的副作用常常导致治疗中断，这引发了一个问题，即患者实际上可能更愿意忍受OAB症状，而不愿承受副作用或复杂的给药方案。药理学的进步最终促使开发出长效剂型的奥昔布宁，即奥昔布宁缓释片（ER），希望这种药物在保持疗效的同时能减少令人烦恼的副作用，并通过每日一次给药方案的便利性提高患者的依从性。本文将综述涉及奥昔布宁ER的主要临床研究，以及它在不同患者群体中的作用和使用时的潜在问题。
